529 organization(s) found
IC–OS (International Cardio–Oncology Society)
The International Cardio-Oncology Society is committed to raising awareness about cardiovascular disease that commonly occurs in patients undergoing treatment for cancer. The ongoing success and complexity of current life-saving therapies has led to the recognition by healthcare providers, patients, and caregivers that cardiac health is vitally important in order to obtain the best patient outcomes. We aim to enhance recognition among providers that prevention and early detection of cardiovascular disease is essential to providing optimal protection for our patients.
IEO (European Institute of Oncology)
The IEO (European Institute of Oncology) is one of the world's most prestigious hospitals and the fastest growing comprehensive cancer centre in Europe. IEO integrates the various areas related to the fight against cancer such as prevention, diagnosis, treatment, training and education, basic and translational research. Mission & Values: The European Institute of Oncology (Istituto Europeo di Oncologia - IEO) strives for excellence in cancer prevention, early diagnosis and effective treatment. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.
INC - Colombia (Instituto Nacional de Cancerología)
The National Cancer Institute (nstituto Nacional de Cancerología [INC], in Spanish) is the only State Entity at the national level, dedicated exclusively to the teaching, prevention, diagnosis, treatment, rehabilitation and intervention of cancer.
INCA (Instituto Nacional de Câncer)
INCA is the body of the Ministry of Health responsible for the development and coordination of integrated actions in the prevention and control of cancer in Brazil. Those actions include hospital care provided directly and free of charge to cancer patients within Brazil's Unified Public Health System (SUS), and interventions in other strategic areas, such as prevention and early detection, training, research and epidemiological information. The Institute coordinates several national programs on cancer control and is equipped with the most modern public diagnostic imaging facility in Latin America.
INCa
In French: "L’Institut national du cancer (INCa) a pour ambition de jouer un rôle d’accélérateur de progrès, en apportant une vision intégrée de l’ensemble des dimensions sanitaire, scientifique, sociale, économique liées aux pathologies cancéreuses ainsi que des différents champs d’intervention (prévention, dépistage, soins, recherche). Ceci, au service des personnes malades, de leurs proches, des usagers du système de santé, de la population générale, des professionnels de santé, des chercheurs et des décideurs."
INCan (Instituto Nacional de Cancerología)
In Spanish: "El Instituto Nacional de Cancerología es un organismo descentralizado de tercer nivel, dependiente de la Secretaría de Salud; que brinda atención médica especializada a enfermos oncológicos siendo además un centro de referencia y órgano rector del cáncer en México. Dirige sus acciones a la atención de pacientes no derechohabientes de la seguridad social, provenientes de todo el país y ha sido política institucional, el otorgar servicios con eficiencia, calidad y calidez, con enfoque multidisciplinario en proceso diagnóstico, tratamiento, rehabilitación y seguimiento. Aunado a las funciones asistenciales como centro de enseñanza médica e investigación."
INEN (Instituto Nacional de Enfermedades Neoplásicas)
In Spanish: “MISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como misión: "Proteger, promover, prevenir y garantizar la atención integral del paciente oncológico, dando prioridad a las personas de escasos recursos económicos; así como, controlar, técnica y administrativamente, a nivel nacional los servicios de salud de las enfermedades neoplásicas y realizar las actividades de investigación y docencia propias del Instituto”. VISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como visión: “Perú libre de cáncer avanzado a través de nuestro liderazgo en políticas y acciones de excelencia que promuevan el acceso universal y equitativo a la prevención y control del cáncer”.”
IOR
The Institute of Oncology Research (IOR), located in Bellinzona (Switzerland) and directed by Prof. Andrea Alimonti, hosts researchers from all over the world performing basic and translational research in oncology with special focus on cancer biology, genomics, molecular oncology and experimental therapeutics. The IOR is affiliated to the Università della Svizzera italiana (USI) and is located in a brand-new high-tech research building that hosts more than 20 different research groups, with state-of-the-art labs and facilities.
ISCaM (International Society for Cancer Metabolism)
The mission of ISCaM (ex ISPDC, International Society for Proton Dynamics in Cancer) is to improve communication and to foster collaborative activities and research programs between European and non European scientists engaged in acidity, proton dynamics, metabolism and microenvironment in cancer research. ISCaM can consolidate, co-ordinate and facilitate International collaboration, facilitate translation of research to clinical development, and fundraise for Networking activities, scientific programs and projects, scientists mobility, young scientists grants and carrier programs.
ISOO (International Society for Oral Oncology)
The purpose of the International Society of Oral Oncology (ISOO) is to promote scientific exchange among health care professionals in oncology about cytotoxic therapy and its impact on the oral environment (including tissues, health and function). The Society provides a multidisciplinary forum for scientists and clinicians to focus on the following areas: · Concepts associated with oral consequences of antineoplastic therapy; · Novel strategies germane to cancer research; · Educational pursuits related to cancer and oral morbidity associated with cancer therapy; and · Scientific diversity through collaboration
ITTC (Innovative Therapies for Children and Adolescents with Cancer) Consortium
ITCC is a clinical trials network focused on delivering new treatments for children and adolescents with cancer through collaborative research and clinical trials. The Innovative Therapies for Children and Adolescents with Cancer (ITCC) consortium stands as one of the largest collaborative groups in the field of paediatric oncology, uniting leading paediatric oncology centres, researchers, and industry partners across Europe and beyond. With 62 sites across 17 countries, we have investigated 75 therapies, completed 55 studies and recruited 3387 patients. By harnessing expertise from various institutions and disciplines, ITCC promotes a multidisciplinary approach to paediatric oncology research. A key focus of ITCC is the development of personalized medicine strategies tailored to the unique characteristics of each child's cancer. This approach aims to optimize treatment effectiveness while minimizing side effects.
Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: antibody Drug Conjugates (ADC), monoclonal antibodies (mAbs) and multi-specific NK Cell Engagers through its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform.
Institut Curie
Made up of an internationally renowned Research Center and a cutting-edge Hospital Group, Institut Curie, the first French cancer center, treats all cancers, even the most rare forms.